I am amazed that any one of the conference large pharma attendees could attend the conference and not be in a meeting discussing terms of buyout or partnership.
Why?
The NYAS treatment data itself is clearly worse than the 2018 JTM paper (and LP SNO update) would have led anybody to expect..